Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases

Internal Medicine

Volumn 46, Issue 16, 2007, Pages 1313-1315

  Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Autoimmune diseases; B cells; CD20

Indexed keywords

B7 ANTIGEN; CD20 ANTIBODY; CD40 LIGAND; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL INTERACTION; CLINICAL TRIAL; CONFERENCE PAPER; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; DRUG TREATMENT FAILURE; HERPES ZOSTER; HOMEOSTASIS; HUMAN; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; MEMORY CELL; PATHOPHYSIOLOGY; PNEUMONIA; REMISSION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION;

EID: 34548381817     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.1914     Document Type: Conference Paper

References (5)

1. Cohen SB, Emery P, Greenwal MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III evaluatin primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54: 2793-2806, 2006.
2. Tokunaga, M, Fujii K, Saito K, et al. Down-regulation of CD40 and CD80 on B cells in patient with life-threatening systemic lupus erythematosus after successfull treatment with rituximab. Rheumatology 44: 176-182, 2005.
3. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 66: 470-477, 2007.
4. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50: 3580-3590, 2004.
5. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multi-center phase I/II trial of rituximab for reflactory systemic lupus erythematosus. Mod Rheumatol 17: 191-197, 2007.